Related Experiment Videos
Hodgkin's disease in a patient with common variable immunodeficiency
C Christopoulos1, T Papadaki, P Vlavianos
1Clinical Haematology Unit, Sismanoglio General Hospital, Athens, Greece.
Journal of Clinical Pathology
|September 1, 1995
Summary
A 61-year-old man with common variable immunodeficiency developed Hodgkin's disease. Chemotherapy induced remission but caused severe side effects, highlighting treatment challenges in immunocompromised patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Common variable immunodeficiency (CVID) is a primary immunodeficiency associated with increased risk of autoimmune diseases, infections, and malignancies.
- T-cell lymphoma with Reed-Sternberg-like cells is a known complication of CVID.
- Distinguishing Hodgkin's disease from T-cell lymphoma in CVID patients is crucial for appropriate management.
Observation:
- A 61-year-old male patient with a history of CVID presented with pyrexia, anemia, and leucopenia.
- Bone marrow biopsy revealed Hodgkin's disease, distinct from T-cell lymphoma based on histopathological and immunophenotypic analysis.
- The patient underwent combination chemotherapy for Hodgkin's disease.
Findings:
- Complete clinical and histological remission of Hodgkin's disease was achieved.
- Treatment was complicated by severe myelosuppression, severe erosive mucositis, and viral retinitis.
- The distinct features of Hodgkin's disease were confirmed, differentiating it from T-cell lymphoma.
Implications:
- This case highlights the importance of vigilant monitoring for malignancies in CVID patients.
- Accurate histopathological and immunophenotypic diagnosis is critical for differentiating Hodgkin's disease from other lymphomas in immunocompromised individuals.
- Management of Hodgkin's disease in CVID requires careful consideration of potential treatment toxicities and complications.